Renowned UK IVF clinic reflects on success with Eeva™. Enhanced patient experience a key benefit of new IVF technology.
Following the birth of the first Eeva baby conceived at the Glasgow Centre for Reproductive Medicine (GCRM), one of the UK’s most innovative IVF clinics and supporter of National Infertility Awareness Week, the clinic identifies the benefits of using the ‘Early Embryo Viablity Assessment’ (Eeva) test, a ground-breaking new approach to IVF that improves embryo selection.
“GCRM was one of the first clinics to offer Eeva and, to date, we’ve used the assessment on more than 150 women” said GCRM Scientist Professor Richard Fleming. “It’s been four months since we welcomed baby Eva Dempster, the world’s first Eeva baby to be conceived at GCRM, and over a year since we started looking after her parents, Susan and David. In that time, the Eeva test has made a significant contribution to the success of IVF at our clinic. It has also given our patients a great deal more insight into their own IVF process, seeing how their embryos develop, which is something completely new. In most cases it provides increased confidence in selecting a particular embryo for transfer, but in some cases the video imaging technology has helped to explain to couples with multiple failed attempts why they aren’t conceiving.”
The Eeva Test is designed to improve in vitro fertilization (IVF) outcomes by providing clinicians and patients with objective information that will enable them to predict embryo viability. The Eeva Test uses software to measure key scientifically and clinically validated cell-division parameters from video images. It is the first and only non-invasive IVF test clinically proven to improve the accuracy of selecting embryos that will likely grow to the blastocyst stage, a critical milestone in embryo development.
Baby Eva was born on 11th June 2013 in Glasgow to parents Susan Walker-Dempster and David Dempster. View the video of her conception here.
Infertility affects one out of every 7 couples in the United Kingdom. The demand for assisted reproduction tools and procedures is growing worldwide. This growth is occurring despite the significant cost per IVF cycle and the low success rate, with approximately one-third of cycles resulting in a live birth. This necessitates the transfer of multiple embryos and/or conducting multiple cycles, leading to greater physical, emotional, practical and financial costs, before determining if pregnancy can be achieved.
GCRM is a member of the ‘Academic Reproductive Partnership’ (ARP). The ARP was formed by the merger of a number of the UK’s leading fertility clinics. The partnership is currently the largest single provider of NHS and private IVF services in the UK.
GCRM provides patients with access to the very latest fertility treatment techniques. Patients also benefit from the sharing of best practice and scientific resources by teams across the UK who are at the pinnacle of the assisted reproduction sector. Please visit www.gcrm.co.uk for more information.
About the Early Embryo Viability Assessment (Eeva) Test
The Eeva test provides IVF clinicians with predictive information about the embryo’s development potential to help improve embryo selection. Eeva’s proprietary software automatically analyzes embryo development against scientifically and clinically validated cell-division parameters identified by researchers at Stanford University in the US. With results from the Eeva test, IVF teams now have predictive and objective information to combine morphological assessment to help improve the embryo selection decision. The Eeva test was validated in a prospective, multi-centre, 54-patient clinical trial with 758 embryos. Embryologists using the Eeva test were able to significantly improve their ability to identify non-viable embryos relative to traditional methods alone. Additionally, Eeva was able to increase the consistency of embryo assessment across embryologists. Results of this study were presented in July 2012 at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting and published by Conaghan et al in Fertility and Sterility, May 2013.
View videos of the technology on YouTube.
Auxogyn is revolutionising the field of reproductive medicine by translating scientific discoveries in early embryo development into clinical tools. The Company’s flagship product, the Eeva™ Test, delivers consistent, objective and quantitative information regarding embryo viability that reproductive endocrinologists and infertility patients can use to make important treatment decisions. Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, Merck Serono Ventures, SR One and TPG Biotech. For more information regarding Auxogyn, please visit www.auxogyn.com.